title: Bevacizumab: a compassionate way of doing business?
authors.forename: A
authors.initials: A
authors.lastname: Spratt
authors.forename: L
authors.initials: L
authors.lastname: Ogunbowale
authors.forename: W
authors.initials: W
authors.lastname: Franks
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic / Q000941:ethics; D012107:Research Design
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab